Rani Therapeutics Holdings Bilan de santé

Santé financière contrôle des critères 3/6

Rani Therapeutics Holdings possède un total de capitaux propres de $5.8M et une dette totale de $28.3M, ce qui porte son ratio d'endettement à 490.1%. Son actif total et son passif total sont $43.5M et de $37.8M.

Informations clés

490.1%

Ratio d'endettement

US$28.31m

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$30.40m
Fonds propres	US$5.78m
Total du passif	US$37.77m
Total des actifs	US$43.54m

Mises à jour récentes de la santé financière

Does Rani Therapeutics Holdings (NASDAQ:RANI) Have A Healthy Balance Sheet?

Jul 16

Is Rani Therapeutics Holdings (NASDAQ:RANI) Weighed On By Its Debt Load?

Mar 20

We're Not Very Worried About Rani Therapeutics Holdings' (NASDAQ:RANI) Cash Burn Rate

Feb 13

Recent updates

Does Rani Therapeutics Holdings (NASDAQ:RANI) Have A Healthy Balance Sheet?

Jul 16

Is Rani Therapeutics Holdings (NASDAQ:RANI) Weighed On By Its Debt Load?

Mar 20

Rani Therapeutics enters $45M loan agreement to support advancement and pipeline development

Aug 08

We're Not Very Worried About Rani Therapeutics Holdings' (NASDAQ:RANI) Cash Burn Rate

Feb 13

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de RANI ( $32.4M ) dépassent ses passifs à court terme ( $20.2M ).

Passif à long terme: Les actifs à court terme de RANI ( $32.4M ) dépassent ses passifs à long terme ( $17.6M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: RANI dispose de plus de liquidités que de sa dette totale.

Réduire la dette: Données insuffisantes pour déterminer si le ratio d'endettement de RANI a diminué au cours des 5 dernières années.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: RANI dispose de moins d'un an de piste de trésorerie sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: RANI dispose de moins d'un an de marge de trésorerie si le flux de trésorerie disponible continue de diminuer à un taux historique de 20.9 % chaque année

Rani Therapeutics Holdings Bilan de santé

Santé financière contrôle des critères 3/6

Informations clés

Mises à jour récentes de la santé financière

Does Rani Therapeutics Holdings (NASDAQ:RANI) Have A Healthy Balance Sheet?

Is Rani Therapeutics Holdings (NASDAQ:RANI) Weighed On By Its Debt Load?

We're Not Very Worried About Rani Therapeutics Holdings' (NASDAQ:RANI) Cash Burn Rate

Recent updates

Rani Therapeutics Announces New Preclinical Pharmacokinetic Data Supporting Transenteric Delivery of GLP-1 Incretin Triagonist

Rani Therapeutics Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $9.999955 million.

Does Rani Therapeutics Holdings (NASDAQ:RANI) Have A Healthy Balance Sheet?

Rani Therapeutics Holdings, Inc., Annual General Meeting, May 29, 2024

New minor risk - Share price stability

Is Rani Therapeutics Holdings (NASDAQ:RANI) Weighed On By Its Debt Load?

Rani Therapeutics Holdings, Inc. to Report Q4, 2023 Results on Mar 20, 2024

Rani Therapeutics Holdings, Inc. to Report Q4, 2023 Results on Mar 20, 2024

New minor risk - Market cap size

Rani Therapeutics Holdings, Inc. Announces Positive Topline Results from Phase 1 Study of Oral Anti-Interleukin 12/23 Antibody (RT-111)

New minor risk - Market cap size

Rani Therapeutics Holdings, Inc. Announces Preclinical Data Regarding A Imimolecular Triagonist Molecule Delivered Via Endoscope

Independent Director recently bought US$102k worth of stock

New major risk - Financial position

Rani Therapeutics Holdings, Inc. Announces Strategic Program Prioritization, Expansion of Manufacturing and Plans to Streamline Business Operations to Support Near-Term Value Drivers and Long-Term Growth of the RaniPill Technology Platform

Price target decreased by 9.9% to US$20.50

Rani Therapeutics Holdings, Inc. Announces Preclinical Data Supporting the Safety and Tolerability of the RaniPill® Drug Delivery Platform Following 60-Day Repeat Administration

Rani Therapeutics Holdings, Inc. Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study

Rani Therapeutics Holdings, Inc. Initiates Phase 1 Study of Rt-111 (Ranipill® Containing Ustekinumab Biosimilar, Ct-P43)

Rani Therapeutics Holdings, Inc. Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies

New major risk - Financial position

Rani Therapeutics Holdings, Inc. Appoints Kate Mckinley as Chief Business Officer

Rani Therapeutics Holdings, Inc. Announces Repeat-Dose Topline Results from RT-102 Phase 1 Study

High number of new directors

Rani Therapeutics Holdings, Inc. Announces New RT-111 Development Program and Provides Corporate Update

Executive Chairman recently sold US$854k worth of stock

Price target decreased to US$24.67

Rani Therapeutics Holdings, Inc. Announces Positive Topline Results from Phase 1 Study of RT-102 in Osteoporosis

Rani Therapeutics Holdings, Inc. announced that it expects to receive $45 million in funding from Avenue Capital Group

Rani Therapeutics enters $45M loan agreement to support advancement and pipeline development

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

High number of new directors

Rani Therapeutics Holdings, Inc., Annual General Meeting, May 25, 2022

Full year 2021 earnings: EPS and revenues miss analyst expectations

Rani Therapeutics Holdings, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2021

We're Not Very Worried About Rani Therapeutics Holdings' (NASDAQ:RANI) Cash Burn Rate

Less than half of directors are independent

Third quarter 2021 earnings released: US$0.16 loss per share

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines